ArticleBreast cancer research : BCR2026
Variation in chemotherapy use across healthcare regions in Sweden and its impact on prognosis in women with HR+/HER2- early breast cancer.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHormone receptor-positive/Human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer accounts for the majority of breast cancer cases. Although chemotherapy can reduce recurrence risk, its use in HR+/HER2- high-risk disease remains complex in clinical practice. We aimed to examine regional variation in chemotherapy use in Sweden and its association with prognosis.
methodsIn this population-based cohort study, we included 61,935 women diagnosed with HR+/HER2- early breast cancer between 2007 and 2023, identified through the Swedish National Quality Register for Breast Cancer. Multivariable logistic regression was applied to identify factors that were associated with chemotherapy use across the Swedish healthcare regions. Overall survival was analysed using Kaplan-Meier estimates and regression standardisation based on Cox models, adjusting for clinicopathological and socioeconomic factors.
findingsChemotherapy was administered to 28·0% of patients, with substantial regional variation (range 23·0-34·7%). Younger age, larger tumour size, node-positive disease, and higher tumour grade were associated with chemotherapy use. Regional differences in 10-year all-cause mortality persisted after adjustment among patients aged ≥ 65 years but were minimal among those aged < 65 years. The healthcare region with the highest chemotherapy use had the lowest mortality. Socioeconomic factors did not alter these associations.
interpretationChemotherapy use in patients with HR+/HER2- early breast cancer varies across the Swedish healthcare regions despite common guidelines. Among young and middle-aged patients, these differences were not associated with survival disparities. In contrast, among patients aged ≥ 65 years, regional differences in treatment remained associated with differences in prognosis also after socioeconomic adjustments, suggesting undertreatment in some regions. These findings support continued efforts to harmonize implementation of treatment recommendations to ensure equitable care for patients with HR+/HER2 - early breast cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.